Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17276342 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zachos G, et al. (2007) Chk1 is required for spindle checkpoint function. Dev Cell 12, 247-60 17276342
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y15-p - CDK1 (human) ▲
Orthologous residues
CDK1 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, B cell lymphoma
 Relevant cell lines - cell types - tissues:  BE colorectal carcinoma, DT40 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  chicken, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol decrease
taxol Chk1 (human) no effect upon treatment-induced increase homozygous null

S7-p - CENPA (human) ▲
Orthologous residues
CENPA (human): S7‑p, CENPA (mouse): ‑, CENPA (rat): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, B cell lymphoma
 Relevant cell lines - cell types - tissues:  BE colorectal carcinoma, DT40 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  chicken, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
taxol Chk1 (human) inhibit treatment-induced increase homozygous null
nocodazole increase
nocodazole Chk1 (human) no effect upon treatment-induced increase homozygous null

S345-p - Chk1 (human) ▲
Orthologous residues
Chk1 (human): S345‑p, Chk1 (mouse): S345‑p, Chk1 (rat): S345‑p, Chk1 (chicken): S345‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, B cell lymphoma
 Relevant cell lines - cell types - tissues:  BE colorectal carcinoma, DT40 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  chicken, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol no change compared to control
etoposide increase

S11-p - H3 (human) ▲
Orthologous residues
H3 (human): S11‑p, H3 (mouse): S11‑p, H3 iso2 (mouse): S11‑p, H3 iso3 (mouse): S11‑p, H3 (rat): S11‑p, H3 iso3 (rat): S11‑p, H3 (pig): S11‑p, H3 (chicken): S11‑p, H3 (cow): S11‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, B cell lymphoma
 Relevant cell lines - cell types - tissues:  BE colorectal carcinoma, DT40 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  chicken, human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE AurB (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
taxol Chk1 (human) inhibit treatment-induced increase homozygous null
siRNA taxol Chk1 (human) inhibit treatment-induced increase
caffeine taxol inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.